Recombinant rabies virus particles presenting botulinum neurotoxin antigens elicit a protective humoral response in vivo

Molecular Therapy Methods and Clinical Development

Volumn 1, Issue , 2014, Pages 14046-

  Hudacek, Andrew W ^a,b   Al Saleem, Fetweh H ^c   Willet, Mallory ^b   Eisemann, Travis ^b   Mattis, Jeffrey A ^a   Simpson, Lance L ^c   Schnell, Matthias J ^b,d  

^a MOLECULAR TARGETING TECHNOLOGIES INC   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B; BOTULINUM TOXIN E; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; PROPIOLACTONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; BOTULISM; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMORAL IMMUNITY; IN VIVO STUDY; LD50; MOUSE; NONHUMAN; PRIORITY JOURNAL; RABIES VIRUS; RECEPTOR BINDING; SEROCONVERSION; SEROTYPE; VACCINE IMMUNOGENICITY; VIROGENESIS; VIRUS INACTIVATION; VIRUS RECOMBINANT;

EID: 84939972348     PISSN: None     EISSN: 23290501     Source Type: Journal    
DOI: 10.1038/mtm.2014.46     Document Type: Article

References (48)

1. 1 Dover, N, Barash, JR, Hill, KK, Xie, G, Arnon, SS, Molecular characterization of a novel botulinum neurotoxin type H gene. J Infect Dis 209 (2014), 192–202.
2. 2 Barash, JR, Arnon, SS, A novel strain of Clostridium botulinum that produces type B and type H botulinum toxins. J Infect Dis 209 (2014), 183–191.
3. 3 Nakamura, K, Kohda, T, Seto, Y, Mukamoto, M, Kozaki, S, Improved detection methods by genetic and immunological techniques for botulinum C/D and D/C mosaic neurotoxins. Vet Microbiol 162 (2013), 881–890.
4. 4 National Center for Infectious Diseases (U.S.). Division of Bacterial and Mycotic Diseases. Botulism in the United States, 1899–1996, 1998, US Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention.
5. 5 Smith, LA, Botulism and vaccines for its prevention. Vaccine 27:suppl 4 (2009), D33–D39.
6. 6 Karalewitz, AP, Barbieri, JT, Vaccines against botulism. Curr Opin Microbiol 15 (2012), 317–324.
7. 7 Arnon, SS, Schechter, R, Inglesby, TV, Henderson, DA, Bartlett, JG, Ascher, MS, et al., Working Group on Civilian Biodefense. Botulinum toxin as a biological weapon: medical and public health management. JAMA 285 (2001), 1059–1070.
8. 8 Aoki, KR, Guyer, B, Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur J Neurol 8:suppl 5 (2001), 21–29.
9. 9 Montecucco, C, Rossetto, O, Schiavo, G, Presynaptic receptor arrays for clostridial neurotoxins. Trends Microbiol 12 (2004), 442–446.
10. 10 Ravichandran, E, Al-Saleem, FH, Ancharski, DM, Elias, MD, Singh, AK, Shamim, M, et al. Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal route. Infect Immun 75 (2007), 3043–3054.
11. 11 Baldwin, MR, Tepp, WH, Przedpelski, A, Pier, CL, Bradshaw, M, Johnson, EA, et al. Subunit vaccine against the seven serotypes of botulism. Infect Immun 76 (2008), 1314–1318.
12. 12 Gao, YL, Gao, S, Kang, L, Nie, C, Wang, JL, Expression of Hc fragment from Clostridium botulinum neurotoxin serotype B in Escherichia coli and its use as a good immunogen. Hum Vaccin 6 (2010), 462–466.
13. 13 Chen, S, Xu, Q, Zeng, M, Oral vaccination with an adenovirus-vectored vaccine protects against botulism. Vaccine 31 (2013), 1009–1011.
14. 14 Yuki, Y, Mejima, M, Kurokawa, S, Hiroiwa, T, Kong, IG, Kuroda, M, et al. RNAi suppression of rice endogenous storage proteins enhances the production of rice-based Botulinum neutrotoxin type A vaccine. Vaccine 30 (2012), 4160–4166.
15. 15 Villaflores, OB, Hsei, CM, Teng, CY, Chen, YJ, Wey, JJ, Tsui, PY, et al. Easy expression of the C-terminal heavy chain domain of botulinum neurotoxin serotype A as a vaccine candidate using a bi-cistronic baculovirus system. J Virol Methods 189 (2013), 58–64.
16. 16 Clayton, MA, Clayton, JM, Brown, DR, Middlebrook, JL, Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli. Infect Immun 63 (1995), 2738–2742.
17. 17 Byrne, MP, Titball, RW, Holley, J, Smith, LA, Fermentation, purification, and efficacy of a recombinant vaccine candidate against botulinum neurotoxin type F from Pichia pastoris. Protein Expr Purif 18 (2000), 327–337.
18. 18 Gil, LA, da Cunha, CE, Moreira, GM, Salvarani, FM, Assis, RA, Lobato, FC, et al. Production and evaluation of a recombinant chimeric vaccine against clostridium botulinum neurotoxin types C and D. PLoS One, 8, 2013, e69692.
19. 19 Elias, M, Al-Saleem, F, Ancharski, DM, Singh, A, Nasser, Z, Olson, RM, et al. Evidence that botulinum toxin receptors on epithelial cells and neuronal cells are not identical: implications for development of a non-neurotropic vaccine. J Pharmacol Exp Ther 336 (2011), 605–612.
20. 20 Mustafa, W, Al-Saleem, FH, Nasser, Z, Olson, RM, Mattis, JA, Simpson, LL, et al. Immunization of mice with the non-toxic HC50 domain of botulinum neurotoxin presented by rabies virus particles induces a strong immune response affording protection against high-dose botulinum neurotoxin challenge. Vaccine 29 (2011), 4638–4645.
21. 21 Blaney, JE, Marzi, A, Willet, M, Papaneri, AB, Wirblich, C, Feldmann, F, et al. Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine. PLoS Pathog, 9, 2013, e1003389.
22. 22 Blaney, JE, Wirblich, C, Papaneri, AB, Johnson, RF, Myers, CJ, Juelich, TL, et al. Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses. J Virol 85 (2011), 10605–10616.
23. 23 Papaneri, AB, Wirblich, C, Cooper, K, Jahrling, PB, Schnell, MJ, Blaney, JE, Further characterization of the immune response in mice to inactivated and live rabies vaccines expressing Ebola virus glycoprotein. Vaccine 30 (2012), 6136–6141.
24. 24 McKenna, PM, Aye, PP, Dietzschold, B, Montefiori, DC, Martin, LN, Marx, PA, et al. Immunogenicity study of glycoprotein-deficient rabies virus expressing simian/human immunodeficiency virus SHIV89.6P envelope in a rhesus macaque. J Virol 78 (2004), 13455–13459.
25. 25 Siler, CA, McGettigan, JP, Dietzschold, B, Herrine, SK, Dubuisson, J, Pomerantz, RJ, et al. Live and killed rhabdovirus-based vectors as potential hepatitis C vaccines. Virology 292 (2002), 24–34.
26. 26 Smith, ME, Koser, M, Xiao, S, Siler, C, McGettigan, JP, Calkins, C, et al. Rabies virus glycoprotein as a carrier for anthrax protective antigen. Virology 353 (2006), 344–356.
27. 27 Schnell, MJ, Buonocore, L, Kretzschmar, E, Johnson, E, Rose, JK, Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles. Proc Natl Acad Sci USA 93 (1996), 11359–11365.
28. 28 McGettigan, JP, Pomerantz, RJ, Siler, CA, McKenna, PM, Foley, HD, Dietzschold, B, et al. Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenic. J Virol 77 (2003), 237–244.
29. 29 Roberts, A, Reuter, JD, Wilson, JH, Baldwin, S, Rose, JK, Complete protection from papillomavirus challenge after a single vaccination with a vesicular stomatitis virus vector expressing high levels of L1 protein. J Virol 78 (2004), 3196–3199.
30. 30 Wertz, GW, Moudy, R, Ball, LA, Adding genes to the RNA genome of vesicular stomatitis virus: positional effects on stability of expression. J Virol 76 (2002), 7642–7650.
31. 31 Tokusumi, T, Iida, A, Hirata, T, Kato, A, Nagai, Y, Hasegawa, M, Recombinant Sendai viruses expressing different levels of a foreign reporter gene. Virus Res 86 (2002), 33–38.
32. 32 Quiñones-Kochs, MI, Schnell, MJ, Buonocore, L, Rose, JK, Mechanisms of loss of foreign gene expression in recombinant vesicular stomatitis viruses. Virology 287 (2001), 427–435.
33. 33 Barrett, PN, Mundt, W, Kistner, O, Howard, MK, Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines. Expert Rev Vaccines 8 (2009), 607–618.
34. 34 Witko, SE, Kotash, CS, Nowak, RM, Johnson, JE, Boutilier, LA, Melville, KJ, et al. An efficient helper-virus-free method for rescue of recombinant paramyxoviruses and rhadoviruses from a cell line suitable for vaccine development. J Virol Methods 135 (2006), 91–101.
35. 35 Jones, RG, Liu, Y, Rigsby, P, Sesardic, D, An improved method for development of toxoid vaccines and antitoxins. J Immunol Methods 337 (2008), 42–48.
36. 36 White, DM, Pellett, S, Jensen, MA, Tepp, WH, Johnson, EA, Arnason, BG, Rapid immune responses to a botulinum neurotoxin Hc subunit vaccine through in vivo targeting to antigen-presenting cells. Infect Immun 79 (2011), 3388–3396.
37. 37 Yu, YZ, Guo, JP, An, HJ, Zhang, SM, Wang, S, Yu, WY, et al. Potent tetravalent replicon vaccines against botulinum neurotoxins using DNA-based Semliki Forest virus replicon vectors. Vaccine 31 (2013), 2427–2432.
38. 38 Yu, YZ, Li, N, Zhu, HQ, Wang, RL, Du, Y, Wang, S, et al. The recombinant Hc subunit of Clostridium botulinum neurotoxin serotype A is an effective botulism vaccine candidate. Vaccine 27 (2009), 2816–2822.
39. 39 Yu, YZ, Zhang, SM, Sun, ZW, Wang, S, Yu, WY, Enhanced immune responses using plasmid DNA replicon vaccine encoding the Hc domain of Clostridium botulinum neurotoxin serotype A. Vaccine 25 (2007), 8843–8850.
40. 40 Zichel, R, Mimran, A, Keren, A, Barnea, A, Steinberger-Levy, I, Marcus, D, et al. Efficacy of a potential trivalent vaccine based on Hc fragments of botulinum toxins A, B, and E produced in a cell-free expression system. Clin Vaccine Immunol 17 (2010), 784–792.
41. 41 Moreira, GM, Cunha, CE, Salvarani, FM, Gonçalves, LA, Pires, PS, Conceição, FR, et al. Production of recombinant botulism antigens: A review of expression systems. Anaerobe 28C (2014), 130–136.
42. 42 Baldwin, MR, Tepp, WH, Pier, CL, Bradshaw, M, Ho, M, Wilson, BA, et al. Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E. Infect Immun 73 (2005), 6998–7005.
43. 43 Smith, LA, Rusnak, JM, Botulinum neurotoxin vaccines: past, present, and future. Crit Rev Immunol 27 (2007), 303–318.
44. 44 Abboud, N, Chow, SK, Saylor, C, Janda, A, Ravetch, JV, Scharff, MD, et al. A requirement for FcγR in antibody-mediated bacterial toxin neutralization. J Exp Med 207 (2010), 2395–2405.
45. 45 Varshney, AK, Wang, X, Aguilar, JL, Scharff, MD, Fries, BC, Isotype switching increases efficacy of antibody protection against staphylococcal enterotoxin B-induced lethal shock and Staphylococcus aureus sepsis in mice. MBio 5 (2014), e01007–e01014.
46. 46 Kozel, TR, The road to toxin-targeted therapeutic antibodies. MBio 5 (2014), e01414–e01477.
47. 47 von Messling, V, Zimmer, G, Herrler, G, Haas, L, Cattaneo, R, The hemagglutinin of canine distemper virus determines tropism and cytopathogenicity. J Virol 75 (2001), 6418–6427.
48. 48 Wirblich, C, Schnell, MJ, Rabies virus (RV) glycoprotein expression levels are not critical for pathogenicity of RV. J Virol 85 (2011), 697–704.